ReviewArchives of dermatological research2024
More yeast, more problems?: reevaluating the role of Malassezia in seborrheic dermatitis.
Review in Archives of dermatological research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Long-Term Safety and Efficacy of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis: A Phase II, Open-Label Trial of up to 52 Weeks.American journal of clinical dermatology · 2026Trial
- Scalp Seborrheic Dermatitis Severity Is Associated with Lipid and Liver-Associated Biochemical Parameters.Journal of clinical medicine · 2026Article
- Maternal diabetes subtypes and offspring cutaneous health: developmental programming of sebaceous gland function in over 330,000 live births.Archives of gynecology and obstetrics · 2026Article
- Seborrheic Dermatitis: Exploring the Complex Interplay withInternational journal of molecular sciences · 2025Review
- Skin Microbiota: Mediator of Interactions Between Metabolic Disorders and Cutaneous Health and Disease.Microorganisms · 2025Review
- Potential Applications of Chitosan in Seborrheic Dermatitis and Other Skin Diseases: A Comprehensive Review.Clinical, cosmetic and investigational dermatology · 2025Review
- Global and Regional Burden of Seborrheic Dermatitis: Trends in Incidence and DALYs, 1990-2021.Clinical, cosmetic and investigational dermatology · 2025Article
- Unexplored fungal diversity on healthy and dandruff skin.Archives of dermatological research · 2024Article
- Review
- Combinatory Use of hLF(1-11), a Synthetic Peptide Derived from Human Lactoferrin, and Fluconazole/Amphotericin B againstAntibiotics (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Seborrheic dermatitis (SD) is an inflammatory skin disorder and eczema subtype increasingly recognized to be associated with significant physical, psychosocial, and financial burden. The full spectrum of SD, including dandruff localized to the scalp, is estimated to affect half of the world's population. Despite such high prevalence, the exact etiopathogenesis of SD remains unclear. Historically, many researchers have theorized a central, causative role of Malassezia spp. based on prior studies including the proliferation of Malassezia yeast on lesional skin of some SD patients and empiric clinical response to antifungal therapy. However, upon closer examination, many of these findings have not been reproducible nor consistent. Emerging data from novel, targeted anti-inflammatory therapeutics, as well as evidence from genome-wide association studies and murine models, should prompt a reevaluation of the popular yeast-centered hypothesis. Here, through focused review of the literature, including laboratory studies, clinical trials, and expert consensus, we examine and synthesize the data arguing for and against a primary role for Malassezia in SD. We propose an expansion of SD pathogenesis and suggest reframing our view of SD to be based primarily on dysregulation of the host immune system and skin epidermal barrier, like other eczemas.
Indexed as
Identifiers
38472524What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.